We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info.

Confirm

Improving the lives of patients is our mission. We are an ambitious and dynamic business with a healthy innovation-driven pipeline that enables us to build on our core expertise in pain. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. This commitment to innovation and thought-leadership means that next generation scientific talent is drawn to us.

Grünenthal. Change is possible.

locations
30

We are present in 30 countries with affiliates in Europe, Latin America and the US.

market presence
100

Our products are sold in more than 100 countries.

employees
5,200

5,200 employees work for our group worldwide.

Success can only be achieved through close collaborations with those who share the same vision.


Please read more about our projects supported by resources of the European Regional Development Fund

... Read More

What we do

As a fully integrated research & development company we bring innovative pain treatments and state-of-the-art technologies to patients.

... Learn more about Grünenthal

Pioneering thinkers

Our passion is innovation. We are driven to seek new solutions for patients with severe diseases and high unmet medical needs – and make these solutions accessible to patients.
... Find out more

Careers

Ready to create a brighter future for our patients?
With us, let your passion and ideas flow and drive innovation to improve our patients’ lives.

... Work with Grünenthal

Featured news & articles

VIVO Pancreas

Focusing on recovery

Operations are stressful enough – without further complications during recovery. Our expert team at Adhesys Medical is targeting a technology that could empower patients to leave hospital sooner and focus on their recovery after pancreas surgery.

Author: Dr. Judita Britner and Dr. Steve Gotzen

Placebo Effect

Placebo Effect and Pain

The role of the placebo effect has become a focus in pain research due to its potential to reduce separation between the drug and control arms, and so influence the outcome in randomised controlled trials (RCTs).

Author: Pain Solve

Neridronate

Giving CRPS patients hope

Neridronate is giving hope to those affected by CRPS – one of the most painful conditions a patient can experience.

Author: Dr. Katrin Fleischer

VIVO Hernia Mesh Fixation

Flexibility brings comfort and safety

Nobody likes complications – especially following an operation. Our innovative surgical glues have the potential to accelerate recovery times and set hernia patients free from post-operative problems.

Author: Kerstin Pawlowsky and Dr. Steve Gotzen

8/28/2018

Aachen, Germany, 28 August 2018 – Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo® marketing authorization for the EU/EEA. Duzallo® is a fixed-dose combination (FDC) therapy that combines allopurinol and lesinurad. It is indicated for the treatment of hyperuricaemia in adult gout patients who have not been able to reach target levels of uric acid serum with a dose of allopurinol alone. Lesinurad is the first innovative uricosuric in gout treatment for over 40 years.

6/21/2018

Aachen, Dortmund and Göttingen, Germany, June 21, 2018 – Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a research collaboration to develop novel therapies for patients suffering from Charcot-Marie-Tooth 1A (CMT1A), an inherited neurological disorder. The collaboration combines the disease proficiency of MPI-EM, the drug discovery expertise of LDC and Grünenthal’s competency in drug discovery and development as well as pain management. The project’s scientific foundation was laid at MPI-EM by Michael Sereda, Klaus-Armin Nave and Moritz Rossner.

6/18/2018

Diegem/Aachen, 18 June 2018. The number of patients suffering from pain is immense. In a recent ‘European Pain Management’ publication (Oxford University Press, 2018), Christopher Eccleston, Bart Morlion and Christopher Wells shared that of approximately 740 million people in the 37 member states of the European Pain Federation EFIC®, approximately 150 million people suffer from chronic pain. This number is equivalent to the populations of both France and Germany combined. The data clearly highlight that pain research is more important than ever. Through the support of the E-G-G Award, young scientists are encouraged to further develop and implement their research ideas.

6/12/2018

Aachen, Germany, 15 June 2018 – Grünenthal has qualified as one of the 25 Best Multinational Workplaces in Europe this year. After 2012 and 2013, this is the third time that Grünenthal, a science-based pharmaceutical company headquartered in Germany, is being awarded in this category. National successes in Italy, Portugal and Spain were the reasons for the decision by the Great Place to Work® (GPtW®) Institute.

6/12/2018

Aachen, Germany, June 12, 2018 – Grünenthal announced today that first patients have been enrolled in two trials of the company’s pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. Neridronate, a bisphosphonate, is an innovative investigational medicine discovered and developed by Abiogen Pharma and now being further developed by Grünenthal for the US territory.